IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(10):2185-2191

Original Article
Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung
cancer

Maoying Fu, Weifei Fan, Xiaolin Pu, Huihui Ni, Wei Zhang, Feng Chang, Li Gong, Lin Xiong, Jun Wang, Xuefeng Gu

Department of Infectious Diseases, The First People’s Hospital of Kunshan Affiliated with Jiangsu University, Suzhou 215000, China;
Department of Hematology and Oncology, Jiangsu Province Geriatric Institute, Nanjing 210029, China; Department of Pathology, The Second
Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China

Received July 23, 2013; Accepted August 17, 2013; Epub September 15, 2013; Published October 1, 2013

Abstract: SH2-containing inositol 5’-phosphatase 2 (SHIP2) is a vital regulator of phosphoinositide pools in metabolic pathways and is
considered to downregulate phosphatidylinositol 3’-kinase signaling, which underlies the development of several kinds of human cancers.
However, SHIP2 expression in non-small cell lung cancer (NSCLC) and its relationship with the clinical characteristics of NSCLC remain
poorly understood. In this study, one-step quantitative reverse transcription-polymerase chain reaction and immunohistochemistry analysis
with tissue microarray was used to evaluate SHIP2 expression in NSCLC and to investigate the relationship of this expression to NSCLC
prognosis. Results showed that the expression of SHIP2 messenger RNA and protein was significantly higher in NSCLC than in
corresponding non-cancerous tissues (both p < 0.05). SHIP2 protein expression in NSCLC was related to lymph node metastasis (p = 0.042),
TNM stage (p = 0.036), and 5-year survival rate (p = 0.046). The Kaplan-Meier method and log-rank test suggested that high SHIP2 expression,
tobacco consumption, and advanced tumor stage were significantly associated with low survival of NSCLC patients. The results of this
research suggested that SHIP2 expression was correlated with malignant phenotypes of NSCLC and may thus serve as a poor prognostic
factor and valuable oncogene for NSCLC. (IJCEP1307040).

Keywords: SHIP2, NSCLC, qPCR, immunohistochemistry, prognosis

Address correspondence to: Dr. Lin Xiong, Department of Pathology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing
210011, China. Tel: +86-25-5850-9833; Fax: +86-25-5850-9994; E-mail: xionglinnjmu@163.com; Dr. Jun Wang, Department of Hematology
and Oncology, Jiangsu Province Geriatric Institute, Nanjing 210029, China. Tel: +86-25-8663-1726; Fax: +86-25-8663-1726; E-mail:
wangjunjs@yeah.net; Dr. Xuefeng Gu, Department of Infectious Diseases, The First People’s Hospital of Kunshan Affiliated with Jiangsu
University, Suzhou 215000, China. Tel: +86-512-5755-9009; Fax: +86-512-5755-9009; E-mail: sani666@163.com